All In Biotech

Drug Trial Radar · NCT03474198

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 675 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

675

Actual

Start

Mar 21, 2018

Primary completion

Jan 20, 2022

Study completion Jan 20, 2022

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National University Hospital, Singapore; Singapore Clinical Research Institute
First posted
Mar 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current standard management strategy for drug-sensitive pulmonary tuberculosis (TB) is to treat with multiple drugs for 6 months, although patients often fail to adhere to the long treatment, leading to poor clinical outcomes including drug resistance, which is expensive and difficult to treat. The TRUNCATE-TB trial evaluates an alternative strategy (the TRUNCATE-TB Management Strategy) comprising treatment for 2 months (8 weeks, extended to 12 weeks if inadequate clinical response) with a regimen predicted to have enhanced sterilising activity ("boosted regimen") and monitoring closely after treatment cessation. Those who relapse (predicted to be always drug sensitive and likely to occur early) will be retreated with a standard 6 month regimen. The trial is a randomized, open-label, multi-arm, multi-stage (MAMS) trial to test the hypothesis that the TRUNCATE-TB Management Strategy is non-inferior to the standard management strategy in terms of longer-term outcomes (clinical status at 96 weeks). If non-inferiority is demonstrated then the advantages/disadvantages of implementing the strategy will be explored in secondary outcomes (from patient and programme perspective). The trial will evaluate the TRUNCATE-TB Management Strategy with 4 potential boosted regimens (180 per arm, total 900 with the standard TB management strategy arm). The boosted regimens include new drugs (licensed drugs, repurposed from other indications) and optimized doses of standard drugs, selected based on consideration of maximal sterilising effect, absence of drug-drug interactions, as well as safety and tolerability over a period of 2 months

Conditions

  • Tuberculosis, Pulmonary

Interventions

  • RifampicinDrug

    10mg/kg

  • IsoniazidDrug

    5mg/kg

  • PyrazinamideDrug

    25mg/kg

  • EthambutolDrug

    15mg/kg

  • LinezolidDrug

    600mg

  • ClofazimineDrug

    200mg

  • RifapentineDrug

    1200mg

  • LevofloxacinDrug

    1000mg

  • BedaquilineDrug

    400mg once daily for 2 weeks then 200mg 3x a week

  • RifampicinDrug

    35mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Unsatisfactory clinical outcome at week 96 after randomisationTime frame: 96 weeks

Locations

18 sites in 6 countries. Site status is shown where the registry gives one.

  • National Institute of TB and Respiratory Diseases

    New Delhi, India

  • Universitas Padjadjaran

    Bandung, Indonesia

  • Persahbahatan Hospital

    Jakarta, Indonesia

  • Wahidin Sudirohusodo Hospital

    Makassar, Indonesia

  • Saiful Anwar Hospital

    Malang, Indonesia

  • Soetomo General Hospital

    Surabaya, Indonesia

  • Perpetual Succour Hospital

    Cebu, Philippines

  • De La Salle Health Sciences Institute

    Manila, Philippines

  • Lung Center Philippines

    Manila, Philippines

  • Philippines Tuberculosis Society Incorporated (PTSI)

    Manila, Philippines

  • Tropical Disease Foundation

    Manila, Philippines

  • Quezon Institute

    Quezon City, Philippines

  • National University Hospital

    Singapore, Singapore

  • King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

  • Central Chest Institute of Thailand

    Nonthaburi, Thailand

  • Infectious Diseases Institute

    Kampala, Uganda

  • Joint Clinical Research Centre

    Kampala, Uganda

  • Joint Clinical Research Centre

    Mbarara, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.